Royalty Pharma PLC (RPRX)
28.08
+0.11
(+0.39%)
USD |
NASDAQ |
May 10, 16:00
28.08
0.00 (0.00%)
After-Hours: 19:23
Royalty Pharma Enterprise Value: 20.95B for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 20.95B |
| May 08, 2024 | 20.96B |
| May 07, 2024 | 21.09B |
| May 06, 2024 | 21.19B |
| May 03, 2024 | 21.15B |
| May 02, 2024 | 21.31B |
| May 01, 2024 | 21.00B |
| April 30, 2024 | 20.83B |
| April 29, 2024 | 21.02B |
| April 26, 2024 | 20.97B |
| April 25, 2024 | 21.02B |
| April 24, 2024 | 20.96B |
| April 23, 2024 | 20.89B |
| April 22, 2024 | 20.89B |
| April 19, 2024 | 21.04B |
| April 18, 2024 | 20.92B |
| April 17, 2024 | 20.79B |
| April 16, 2024 | 20.73B |
| April 15, 2024 | 21.08B |
| April 12, 2024 | 21.06B |
| April 11, 2024 | 21.44B |
| April 10, 2024 | 21.61B |
| April 09, 2024 | 21.74B |
| April 08, 2024 | 21.52B |
| April 05, 2024 | 21.50B |
| Date | Value |
|---|---|
| April 04, 2024 | 21.29B |
| April 03, 2024 | 21.32B |
| April 02, 2024 | 21.61B |
| April 01, 2024 | 21.82B |
| March 28, 2024 | 22.03B |
| March 27, 2024 | 22.06B |
| March 26, 2024 | 21.96B |
| March 25, 2024 | 21.99B |
| March 22, 2024 | 21.98B |
| March 21, 2024 | 22.05B |
| March 20, 2024 | 22.04B |
| March 19, 2024 | 21.94B |
| March 18, 2024 | 21.88B |
| March 15, 2024 | 21.90B |
| March 14, 2024 | 21.79B |
| March 13, 2024 | 21.81B |
| March 12, 2024 | 22.02B |
| March 11, 2024 | 21.90B |
| March 08, 2024 | 22.03B |
| March 07, 2024 | 21.88B |
| March 06, 2024 | 21.74B |
| March 05, 2024 | 21.61B |
| March 04, 2024 | 21.81B |
| March 01, 2024 | 21.83B |
| February 29, 2024 | 22.01B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
19.54B
Minimum
Sep 21 2023
28.75B
Maximum
Jan 26 2021
24.43B
Average
24.81B
Median
Jul 01 2020
Enterprise Value Benchmarks
| Viatris Inc | 30.25B |
| Amgen Inc | 222.12B |
| Arrowhead Pharmaceuticals Inc | 2.861B |
| Pacira BioSciences Inc | 1.584B |
| Maravai LifeSciences Holdings Inc | 1.628B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 494.34M |
| Revenue (Quarterly) | 596.07M |
| Total Expenses (Quarterly) | -16.83M |
| EPS Diluted (Quarterly) | 1.10 |
| Profit Margin (Quarterly) | 82.93% |
| Earnings Yield | 8.97% |
| Operating Earnings Yield | 8.81% |
| Normalized Earnings Yield | 7.106 |